Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Other Accumulated Expenses (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Other Accumulated Expenses data on record, last reported at $580000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 74.7% year-over-year to $580000.0; the TTM value through Sep 2025 reached $580000.0, up 74.7%, while the annual FY2024 figure was $249000.0, 134.91% up from the prior year.
  • Other Accumulated Expenses reached $580000.0 in Q3 2025 per ZBIO's latest filing, up from $508000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $580000.0 in Q3 2025 and bottomed at $106000.0 in Q4 2023.
  • Average Other Accumulated Expenses over 3 years is $359833.3, with a median of $358000.0 recorded in 2024.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 134.91% in 2024, then soared 74.7% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $106000.0 in 2023, then surged by 134.91% to $249000.0 in 2024, then soared by 132.93% to $580000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $580000.0 in Q3 2025, $508000.0 in Q2 2025, and $384000.0 in Q1 2025.